RDIF and Minapharm agree to produce over 40 million doses of the Sputnik V vaccine in Egypt
PR89134
MOSCOW, CAIRO and BERLIN, Apr. 22, 2021 /PRNewswire=KYODO JBN/--
The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund),
Egypt's Minapharm, the regional leader in recombinant DNA technology, and its
Berlin-based subsidiary, ProBioGen AG, announce the agreement to produce over
40 million doses per year of the world's first registered vaccine against
COVID-19, Sputnik V.
The parties intend to commence technology transfer immediately. The rollout of
the vaccine is expected in 3Q 2021.
RDIF and Minapharm will initially supply over 40 million doses per year.
Production will take place in Minapharm's biotech facility in Cairo for global
distribution.
Minapharm's German subsidiary, ProBioGen AG, aims to undertake efforts for
process optimization to further increase the production scale, taking advantage
of its expertise in viral vector technology and manufacturing process
development for vaccines and gene therapy.
To date, Sputnik V has been registered in 61 countries globally covering a
total population of over three billion people. Sputnik V vaccine demonstrated
efficacy of 97.6%, based on the analysis of data on the infection rate of
coronavirus among those in Russia vaccinated with both components of the
vaccine.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented:
"Agreement with Minapharm marks our first partnership in the MENA region to
produce Sputnik V. RDIF is in cooperation with the leading pharmaceutical
producers globally as Sputnik V is registered in 61 countries. The Russian
vaccine is highly efficient and trusted by regulators around the world and
makes a huge contribution in the fight against coronavirus."
Wafik Bardissi, PhD, Chairman and CEO of Minapharm, added:
"This agreement is a natural expansion to Minapharm's regional leadership in
biotechnologies, capitalizing on the vast international experience in cellular
engineering and adenoviral vector technology of its wholly owned German
subsidiary ProBioGen AG. We are pleased to join the RDIF in combatting the
global COVID-19 pandemic."
Sputnik V has a number of key advantages:
- Efficacy of Sputnik V is 97.6% based on the analysis of data on the
coronavirus infection rate among those in Russia vaccinated with both
components of Sputnik V from December 5, 2020 to March 31, 2021.
- The Sputnik V vaccine is based on a proven and well-studied platform of human
adenoviral vectors, which cause the common cold and have been around for
thousands of years.
- Sputnik V uses two different vectors for the two shots in a course of
vaccination, providing immunity with a longer duration than vaccines using the
same delivery mechanism for both shots.
- The safety, efficacy and lack of negative long-term effects of adenoviral
vaccines have been proven by more than 250 clinical studies over two decades.
- There are no strong allergies caused by Sputnik V.
- The storage temperature of Sputnik V at +2+8 C means it can be stored in a
conventional refrigerator without any need to invest in additional cold-chain
infrastructure.
- The price of Sputnik V is less than $10 per shot, making it affordable around
the world.
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund
established in 2011 to make equity co-investments, primarily in Russia,
alongside reputable international financial and strategic investors. RDIF acts
as a catalyst for direct investment in the Russian economy. RDIF's management
company is based in Moscow. Currently, RDIF has experience of the successful
joint implementation of more than 80 projects with foreign partners totaling
more than RUB1.9 tn and covering 95% of the regions of the Russian Federation.
RDIF portfolio companies employ more than 800,000 people and generate revenues
which equate to more than 6% of Russia's GDP. RDIF has established joint
strategic partnerships with leading international co-investors from more than
18 countries that total more than $40 bn. Further information can be found at
rdif.ru.[ https://rdif.ru/ ]
Minapharm Pharmaceuticals is a leading pharmaceutical company in Egypt and the
Middle East and the premier biopharmaceutical company in Africa with over 20
years of experience in cellular and bioprocess engineering. Headquartered in
Cairo, Minapharm commercializes over 100 life-saving and life-enhancing
products ranging from small molecules to complex genetically-engineered
proteins, with an impressive immunotherapy pipeline. Minapharm's wholly owned
Berlin-based subsidiary, ProBioGen AG, is a world-renowned contract development
and manufacturing organisation (CDMO), a cell line-engineering specialist and a
provider of proprietary protein and viral vector technologies to large pharma
and the global biotech industry. Minapharm has established an integrated
business model making it to-date the only gene-to-market biopharmaceutical
company in the region. Minapharm employs a collective workforce of over 1400
and is listed on the Cairo and Alexandria stock exchange (symbol: MIPH).
Further information can be found at www.minapharm.com. [
Photo - https://mma.prnewswire.com/media/1493091/Sputnik_V.jpg
Logo -
https://mma.prnewswire.com/media/1492894/Minapharm_Pharmaceuticals_Logo.jpg
Logo - https://mma.prnewswire.com/media/1492895/RDIF_Logo.jpg
Source: Minapharm Pharmaceuticals and RDIF
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。